AI Article Synopsis
- - A nurse contracted Hepatitis C virus (HCV) from a needlestick and was effectively treated with a short course of interferon (IFN) therapy. - The source of the infection was a chronic HCV patient who did not respond to IFN treatment and had a specific HCV genotype (1b) with a mutation linked to IFN resistance. - Despite the source patient's strain being thought to be resistant to IFN, the nurse with acute HCV infection achieved a sustained response to the therapy.
Article Abstract
Hepatitis C virus (HCV) was successfully eradicated by a short course of interferon (IFN) therapy in a nurse with acute HCV infection from a needlestick accident. The source patient had chronic hepatitis C and was a nonresponder to IFN therapy. The HCV genotype was 1b in patients, and a single point mutation (H-->R in amino acid 2218) was observed in the IFN sensitivity-determining region of the nonstructural 5A gene, in comparison with sequences of HCV-J, in HCV RNA from both the source patient (before and after IFN therapy) and the recipient (before IFN therapy). Though the strain transmitted was believed to be IFN-resistant in the patient with chronic hepatitis, the patient with acute hepatitis had a sustained response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/003655200451270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Switching Drivers: Epigenetic Rewiring to Genetic Progression in Glioma.
Cancer Res
December 2024
Lunenfeld-Tanenbaum Research Institute, Toronto, Canada.
IDH-mutant low-grade gliomas (LGGs) are slow-growing brain tumors that frequently progress to aggressive high-grade gliomas that have dismal outcomes. In a recent study, Wu and colleagues provide critical insights into the mechanisms underlying malignant progression by analyzing single-cell gene expression and chromatin accessibility across different tumor grades. Their findings support a two-phase model: in early stages, tumors are primarily driven by oligodendrocyte precursor-like cells and epigenetic alterations that silence tumor suppressors like CDKN2A and activate oncogenes such as PDGFRA.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Background: Individuals with Down Syndrome (DS) exhibit a genetic form of Alzheimer's disease (AD). In this study, we leveraged biobanked plasma samples from a completed clinical trial focused on anti-inflammatory treatment, Vitamin E, for DS. The trial's primary endpoint was on cognition, and Vitamin E treatment was not found to be significantly beneficial.
View Article and Find Full Text PDFPhenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone promote antiviral immune response by activating NF-ĸB.
Nat Commun
January 2025
Ruminant Diseases Research Center, College of Life Sciences, Shandong Normal University, Jinan, Shandong, China.
Phenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone have been identified as tumor suppressors. However, their roles in virus infection remain unclear. Here, we demonstrate that PBLD upregulates the type I interferon (IFN-I) response through activating NF-kappaB (NF-κB) signaling pathway to resist viral infection in cells and mice.
View Article and Find Full Text PDFA smart responsive NIR-operated chitosan-based nanoswitch to induce cascade immunogenic tumor ferroptosis via cytokine storm.
Carbohydr Polym
March 2025
College of Biological Science and Medical Engineering, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, Donghua University, Shanghai 201620, PR China. Electronic address:
In this work we present a near-infrared (NIR)-operated nanoswitch based on chitosan nanoparticles (EpCAM-CS-co-PNVCL@IR780/IMQ NPs) that induces cascade immunogenic tumor ferroptosis via cytokine storm. The formulation was prepared by loading a photosensitiser (IR780) and an immunotherapeutic drug (imiquimod; IMQ) into temperature- and pH-responsive chitosan-based NPs functionalized with tumor-targeting aptamers. The EpCAM aptamer can chaperone the NPs selectively into cancer cells, and allow them to enter the cell nucleus.
View Article and Find Full Text PDFTrabectedin enhances the antitumor effects of IL-12 in triple-negative breast cancer.
Cancer Immunol Res
January 2025
The Ohio State University, Columbus, OH, United States.
Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 in triple-negative breast cancer (TNBC). In vitro treatment of healthy donor NK cells with trabectedin increased expression of the activation marker CD69 and mRNA expression of T BET (Tbx21), the cytotoxic ligands TRAIL (TNFSF10) and Fas ligand (FASLG) and the dendritic cell (DC)-recruiting chemokine lymphotactin (XCL1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!